. Author manuscript; available in PMC: 2011 Sep 22.

Published in final edited form as: Psychiatr Clin North Am. 2010 Mar;33(1):181–224. doi: 10.1016/j.psc.2009.12.001

Table 3.

Candidate Gene Studies From CATIE and Genome-wide Association Studies of Treatment Responses to Antipsychotics

Author (Year)	Drug	Gene(s)	Outcome	Sample Size	Key Finding(s)
Candidate gene studies from CATIE
Grossman (2008)	CATIE^*	CYP2D6, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP1A4, CYP3A5, CYP3A4, ABCB1, FMO3 UGT1A4	Optimized dose Treatment stop due to side effects Tardive dyskinesia	750	No associations
Campbell (2008)	CATIE^*	RGS4	Efficacy	678	Suggestive association
Need (2009)	CATIE^*	118 genes	21 phenotypes	756	Multiple suggestive associations
Tsai (2009)	CATIE^*	128 genes	Tardive dyskinesia	710	No associations
Genome-wide association studies
McClay (2009)	CATIE^*	Affymetrix 500K	Efficacy	738	Significant association in 4p15
Alkelai (2009)	CATIE^*	Affymetrix 500K plus custom 164K fill-in chip	Antipsychotic-induced parkinsonism	397	Suggesitve associations in EPF1, NOVA1, FIGN
Aberg (2009)	CATIE^*	Affymetrix 500K	Extra-pyramidal side effects	738	Significant associations in 11q24 and ZNF202
Lavedan (2009)	Iloperidone	Affymetrix 500K	Efficacy	426	Suggestive association with NPAS3
Volpi (2009)	Iloperidone	Affymetrix 500K	QT interval prolongation	183	Suggestive association with CERKL and SLCO3A1

In CATIE, patients were treated with up to 5 different antipsychotics: olanzapine, quetiapine, risperidone, ziprasidone, perphenazine